Member Info for Wiggly

The order amount is above your available spend.

Approximate order amount: 1,000,000 x 1.24 = £1,240,000.00. Available spend: £0.00

Please either amend the quantity you have entered, or fund your account by clicking Add Cash

I doubt you can buy at present? I cant check as fully loaded with AVCT....

Concerning the optimisation process currently underway... I now strongly believe we could be optimising from 98% to 99%....

That's very interesting. After watching the recent webinar, would you have guessed Sona were into a 96% winner?

Now extremely confident that Avct will deliver the Best possible.

Its coming!

If Alistair said 2 weeks for optimisation then expect max 1. He definitely wouldn't say 2 weeks and risk it running for 3..

Some key takeaways..

When discussing the LFT Sir Ali lists the key markets in the following order:

1. Health care professionals
2. Corporates
3. Consumers

Accuracy likely to be high imo.....

And that, Ladies and Gentlemen, is why Confiner are here - the risk/reward investment case related to the cancer treatment.

Perhaps, much like I think big pharma will have to act sooner than typically is the norm, Conifer were also forced to act (paying a high price per share) more quickly due to the unfolding Covid story and the blue sky benefits that it looks likely to deliver to AVCT.

Bigbitenow, it is great to have you share your thoughts on LSE, I hope you do so more often.

I think you hit the nail on the head with the following comment;

"It is also about what those revenues can do for a business that has for some time, had exciting ideas and potential, but didn't always have the attention and certainly not the finance, to exploit the opportunity thoroughly enough"

Without trying to ramp, I also think this will force the hand of big pharma to act sooner than is the norm with tech development.

MY view is that Fact 4 is the most meaningful.

Note that it does not say following the SUCCESSFUL optimisation it says;

Following the optimisation of the lateral flow test by Cytiva the design will then be transferred

This is a fact, it will happen.

We have 4 INDEPENDENT, highly respected sources, highlighting the huge potential of the Affirmers. Clearly, this is not collusion simply to pump a placing.

This is the real deal.

Fact 1:

The Affimer reagents have worked well in lateral flow test strips and Cytiva are VERY encouraged by the initial data.

Source: Klaus Hochleitner, Global Lead, Technology Product Specialist at Cytiva

Fact 2:

Adeptrix are excited to apply Avacta's Affimer reagents to monitor COVID-19 infection because they are very well suited for large-scale manufacturing and have stable lot-to-lot performance due to it being a recombinant technology. The BAMS assay for the spike protein serves as a useful diagnostic tool because this particular viral protein is displayed on the surface of the virus particle and directly involved in engaging host cells (via ACE2 receptor) during infection. For this reason, the same BAMS assay for the spike protein can also be used for drug development efforts to screen compounds that block interaction with host cells through the ACE2 receptor to prevent virus infection.

Source: Dr. Jeffrey C. Silva, Director of Product Development, Adeptrix Corporation

Fact 3:

The infectivity assays that Glasgow University have carried out with the Affimer reagents have gone very well and they show that there are a number of them that are potent inhibitors of a SARS-COV-2 model virus entry into human cells.
Given the excellent performance of these novel reagents in the assays, and the other benefits of Affimer reagents, there should be considerable interest from potential partners in developing them as a therapy for COVID-19

Source: Professor David Bhella, Professor of Structural Virology (Centre for Virus Research) at the University of Glasgow

Fact 4:

Following the optimisation of the lateral flow test by Cytiva the design will then be transferred to manufacturing partners in the UK that are currently being put in place by Avacta. The Company is working with these manufacturers to compress the normal manufacturing, clinical validation and regulatory timelines in order to bring a product to market as quickly as possible.

Source: Sir Al, CEO

It is all there in black and white, simple to understand.

Ignore the noise, focus on the facts.

Oh oh Global_2017 - if I were you I would get back in quick....

Look like buys?

As certain new posters, such as JJMills, try to plant doubt, it is worth remembering the facts.

Regarding US manufacture, pay specific attention to Fact 1 below, then ask yourself why JJMills may be questioning the reality.

separate/independent sources advising;

Fact 1:

The Affimer reagents have worked well in lateral flow test strips and Cytiva are VERY encouraged by the initial data.

Source: Klaus Hochleitner, Global Lead, Technology Product Specialist at Cytiva

Fact 2:

Adeptrix are excited to apply Avacta's Affimer reagents to monitor COVID-19 infection because they are very well suited for large-scale manufacturing and have stable lot-to-lot performance due to it being a recombinant technology. The BAMS assay for the spike protein serves as a useful diagnostic tool because this particular viral protein is displayed on the surface of the virus particle and directly involved in engaging host cells (via ACE2 receptor) during infection. For this reason, the same BAMS assay for the spike protein can also be used for drug development efforts to screen compounds that block interaction with host cells through the ACE2 receptor to prevent virus infection.

Source: Dr. Jeffrey C. Silva, Director of Product Development, Adeptrix Corporation

Fact 3:

The infectivity assays that Glasgow University have carried out with the Affimer reagents have gone very well and they show that there are a number of them that are potent inhibitors of a SARS-COV-2 model virus entry into human cells.
Given the excellent performance of these novel reagents in the assays, and the other benefits of Affimer reagents, there should be considerable interest from potential partners in developing them as a therapy for COVID-19

Source: Professor David Bhella, Professor of Structural Virology (Centre for Virus Research) at the University of Glasgow

Fact 4:

Following the optimisation of the lateral flow test by Cytiva the design will then be transferred to manufacturing partners in the UK that are currently being put in place by Avacta. The Company is working with these manufacturers to compress the normal manufacturing, clinical validation and regulatory timelines in order to bring a product to market as quickly as possible.

Source: Sir Al, CEO

It is all there in black and white, simple to understand.

Ignore the noise, focus on the facts.

Pure speculation however, could Cytiva, via lump sum payment to AVCT, secure exclusive rights to the US market?

4 separate/independent sources advising;

Fact 1:

The Affimer reagents have worked well in lateral flow test strips and Cytiva are VERY encouraged by the initial data.

Source: Klaus Hochleitner, Global Lead, Technology Product Specialist at Cytiva

Fact 2:

Adeptrix are excited to apply Avacta's Affimer reagents to monitor COVID-19 infection because they are very well suited for large-scale manufacturing and have stable lot-to-lot performance due to it being a recombinant technology. The BAMS assay for the spike protein serves as a useful diagnostic tool because this particular viral protein is displayed on the surface of the virus particle and directly involved in engaging host cells (via ACE2 receptor) during infection. For this reason, the same BAMS assay for the spike protein can also be used for drug development efforts to screen compounds that block interaction with host cells through the ACE2 receptor to prevent virus infection.

Source: Dr. Jeffrey C. Silva, Director of Product Development, Adeptrix Corporation

Fact 3:

The infectivity assays that Glasgow University have carried out with the Affimer reagents have gone very well and they show that there are a number of them that are potent inhibitors of a SARS-COV-2 model virus entry into human cells.
Given the excellent performance of these novel reagents in the assays, and the other benefits of Affimer reagents, there should be considerable interest from potential partners in developing them as a therapy for COVID-19

Source: Professor David Bhella, Professor of Structural Virology (Centre for Virus Research) at the University of Glasgow

Fact 4:

Following the optimisation of the lateral flow test by Cytiva the design will then be transferred to manufacturing partners in the UK that are currently being put in place by Avacta. The Company is working with these manufacturers to compress the normal manufacturing, clinical validation and regulatory timelines in order to bring a product to market as quickly as possible.

Source: Sir Al, CEO

It is all there in black and white, simple to understand.

Ignore the noise, focus on the facts.

But covid is over they said? The covid play bubble has burst they said?

In a Senate hearing Tuesday, Dr. Anthony Fauci, the director of the National Institute for Allergy and Infectious Diseases, said, "I would not be surprised if we go up to 100,000 [cases] a day if this does not turn around."

"We can’t just focus on the areas that are having the surge -- it puts the entire country at risk," Fauci said. "I’m very concerned because it could get very bad."

Fauci's ominous comments came as he responded to questions from Sen. Elizabeth Warren, D-Mass., who said, "We can’t keep pretending this virus is getting better."

Out of control, completely out of control.

I wonder if that number, 100k per day, will coincide with avct LFT market entrance.

has 'way too much virus' to control

Dr Anne Schuchat, principal deputy director of the Centers for Disease Control and Prevention (CDC), has warned that the US is not responding like other countries who have shown success in containing the coronavirus, and has allowed the virus to spread much more widely and rapidly.

"We're not in the situation of New Zealand or Singapore or Korea where a new case is rapidly identified and all the contacts are traced and people are isolated who are sick and people who are exposed are quarantined and they can keep things under control," the top expert said in an interview with The Journal of the American Medical Association on Monday.

"We have way too much virus across the country for that right now, so it's very discouraging."

They could start trying by forcing all employers to mandatory test their staff on arrival, with the Danaher POC LFT.

I completely agree, 1ss. For me, this started as a trade however looking around for somewhere better (risk vs reward) I see no reason other than to stick around for the long term.

Ophidian,

Did we? I assume you are referring to the June 24th RNS which states;

"These data show that the test strips detect the spike protein in model samples at concentrations within the clinical range found in saliva of patients with COVID-19"

I do not interpret the above as release of data.

I am hopeful we will receive real data today however I am here for the long term, not currently leveraged, so happy to wait.